LONDON, UNITED KINGDOM--(Marketwired - Jan 25, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that the Company is actively selling Phytofare® in Africa, Europe and Australia, where various customers use Phytofare® as the active ingredient in their formulated products. Sales of Phytofare® to United States customers are considered imminent, with sales to China anticipated later in the year.

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, stated, "We initially rolled out the product release of Phytofare® in South Africa as it was in our backyard, and we could more quickly react to customer needs and inquiries. With any new product, there is a certain inherent process of customer education necessary and Phytofare® was no different. We have been able to scale up production as demand has increased and are now able to serve manufacturers throughout Western Europe and, more recently, in Australia.

"In South Africa," Mr. Cottrell-Duffield continued, "Phytofare® is the active ingredient in LipoXT, which has become the leading weight loss product in the country. The manufacturer, USN, anticipates expanding sales outside of Africa thanks to the tremendous customer response. We are also now poised to commence selling Phytofare® to manufacturers in the United States as our production is now at a level where we believe can support this market. We know that it will be huge milestone for our US investors to be able to see products on the shelf containing Phytofare®."

Addressing the Chinese market, Mr. Cottrell-Duffield added, "Being able to sell into China, which obviously is a huge market opportunity, has always presented its unique set of challenges. Fortunately, our sales relationships in Australia, where Phytofare® enjoys government acceptance, enables us to also meet the strict Chinese requirement for import. We are actively working on introducing Phytofare® into China and anticipate successfully entering this market within a few months."

Phytofare® is a green-tea derived extract unique in that it contains all eight major catechins found in green tea while also delivering ten times greater bioavailability over generic green tea extracts. Unlike other catechin extracts, Phytofare® remains in the bloodstream at therapeutic levels for over 24 hours, where it can offer increased thermogenic benefits as well as anti-oxidant protection.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.